3/24
01:29 pm
tars
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade [Yahoo! Finance]
Low
Report
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade [Yahoo! Finance]
3/23
08:46 am
tars
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus [Yahoo! Finance]
Low
Report
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus [Yahoo! Finance]
3/23
08:30 am
tars
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
Medium
Report
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
3/18
06:57 am
tars
Tarsus Pharmaceuticals (TARS) was upgraded by Lifesci Capital to "strong-buy".
Medium
Report
Tarsus Pharmaceuticals (TARS) was upgraded by Lifesci Capital to "strong-buy".
3/11
02:47 pm
tars
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/9
12:27 am
tars
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance [Yahoo! Finance]
Low
Report
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance [Yahoo! Finance]
3/6
10:36 am
tars
Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating [Yahoo! Finance]
Low
Report
Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating [Yahoo! Finance]
2/28
01:30 am
tars
Low
Report
2/27
06:26 am
tars
Tarsus Pharmaceuticals (TARS) was downgraded by Zacks Research from "strong-buy" to "hold".
Low
Report
Tarsus Pharmaceuticals (TARS) was downgraded by Zacks Research from "strong-buy" to "hold".
2/26
04:30 pm
tars
Tarsus to Participate in Upcoming Investor Conferences
Low
Report
Tarsus to Participate in Upcoming Investor Conferences
2/26
12:42 am
tars
Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines? [Yahoo! Finance]
Medium
Report
Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines? [Yahoo! Finance]
2/25
12:58 pm
tars
Tarsus Pharmaceuticals (TARS) had its price target raised by Oppenheimer Holdings, Inc. from $95.00 to $105.00. They now have an "outperform" rating on the stock.
Medium
Report
Tarsus Pharmaceuticals (TARS) had its price target raised by Oppenheimer Holdings, Inc. from $95.00 to $105.00. They now have an "outperform" rating on the stock.
2/25
09:39 am
tars
Tarsus Pharmaceuticals (TARS) had its price target raised by Guggenheim from $87.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
Tarsus Pharmaceuticals (TARS) had its price target raised by Guggenheim from $87.00 to $90.00. They now have a "buy" rating on the stock.
2/24
12:43 pm
tars
Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/24
12:21 am
tars
Tarsus Pharmaceuticals Inc (TARS) Q4 2025 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]
Low
Report
Tarsus Pharmaceuticals Inc (TARS) Q4 2025 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]
2/23
09:12 pm
tars
Tarsus Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Tarsus Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/23
04:05 pm
tars
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
High
Report
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
2/18
08:30 am
tars
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
Low
Report
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
2/17
04:30 pm
tars
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
Low
Report
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
2/5
09:12 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/27
05:58 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/24
05:10 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/15
06:06 am
tars
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]
Low
Report
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]